ZMB Member Jens Siveke
ZMB Member
Jens Siveke
Next ZMB-Member
Prof. Dr. Jens Siveke
West German Cancer Center (WTZ)
and
Division for Solid Tumor Translational Oncology
DKTK/DKFZ partner site Essen
Medical Faculty
University Duisburg-Essen
45141 Essen
- +49 201 723 3704
- Website
- Selected Publications
- Publication Metrics
- ZMB Research Program
Oncology
Research Overview
- Pancreatic Cancer and hard to treat cancers (eg NUT midline carcinoma, uveal melanoma)
- Preclinical Model Systems (organoids, PDX, GEMM)
- Tumor phenotypes (Tumor Heterogeneity, Cellular Plasticity, (epi)genomic alterations)
- Tumor Microenvironment and Immunooncology
- Drug Discovery
- Moleacular Imaging and Imaging-guided Therapy (Theranostics)
- Liquid Biopsy
Selected Publications
-
A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in GlioblastomaIn: Clinical Cancer Research Vol. 29 (2023) Nr. 2, pp. 488 - 500Online Full Text: dx.doi.org/ (Open Access)
-
LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer GrowthIn: Clinical Cancer Research Vol. 29 (2023) Nr. 6, pp. 1137 - 1154Online Full Text: dx.doi.org/
-
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer EntitiesIn: Clinical Cancer Research Vol. 28 (2022) Nr. 19, pp. 4346 - 4353Online Full Text: dx.doi.org/ (Open Access)
-
Implementing cell-free DNA of pancreatic cancer patient–derived organoids for personalized oncologyIn: JCI Insight Vol. 5 (2020) Nr. 15, pp. e137809Online Full Text: dx.doi.org/ (Open Access)
-
Loss of Wasl improves pancreatic cancer outcomeIn: JCI Insight Vol. 5 (2020) Nr. 10, e127275Online Full Text: dx.doi.org/ (Open Access)
-
Serial Circulating Tumor DNA Mutational Status in Patients with KRAS-Mutant Metastatic Colorectal Cancer from the Phase 3 AIO KRK0207 TrialIn: Clinical Chemistry Vol. 66 (2020) Nr. 12, pp. 1510 - 1520Online Full Text: dx.doi.org/ (Open Access)
-
Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinomaIn: Oncogene Vol. 39 (2020) Nr. 24, pp. 4770 - 4779Online Full Text: dx.doi.org/ (Open Access)
-
Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-Mutant Pancreatic and Colorectal CancerIn: Cancer Research Vol. 79 (2019) Nr. 9, pp. 2367 - 2378Online Full Text: dx.doi.org/
-
Notch-induced myeloid reprogramming in spontaneous pancreatic ductal adenocarcinoma by dual genetic targetingIn: Cancer Research Vol. 78 (2018) Nr. 17, pp. 4997 - 5010Online Full Text: dx.doi.org/ (Open Access)
-
Co-clinical assessment of tumor cellularity in pancreatic cancerIn: Clinical Cancer Research Vol. 23 (2017) Nr. 6, pp. 1461 - 1470Online Full Text: dx.doi.org/
-
Kras(G12D) induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cellsIn: Oncogene Vol. 35 (2016) Nr. 29, pp. 3880 - 3886Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
EGF Receptor Is Required for KRAS-Induced Pancreatic TumorigenesisIn: Cancer Cell Vol. 22 (2012) Nr. 3, pp. 304 - 317Online Full Text: dx.doi.org/ (Open Access)
-
Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinomaIn: Proceedings of the National Academy of Sciences of the United States of America Vol. 107 (2010) Nr. 30, pp. 13438 - 13443Online Full Text: dx.doi.org/ (Open Access)